CD52 and neoplasm: Regarding trial target studies, anti-tumor immunity and cell primarily involves molecules associated with immune responses, including CD19 (4 trials, 8.5%), membrane-spanning 4-domains A1 (4 trials, 8.5%), and CD52 (3 trials, 6.4%).